title: The long-lasting effect of ferumoxytol on abdominal magnetic resonance imaging.
abstract: Ferumoxytol is a parenteral iron therapy that the Food and Drug Administration recently approved for the treatment of iron-deficiency anemia. The form of the iron, ultrasmall superparamagnetic iron oxide nanoparticles, causes T1, T2, and T2* shortening on magnetic resonance imaging, which can mimic hemosiderosis. We report such a case, with laboratory findings that demonstrate normal iron stores, and discuss the potential implications.
authors.affiliation: From the *Department of Diagnostic Imaging, The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI; and †Hematology & Oncology Associates of RI, Inc, Cranston, RI.
authors.forename: Aaron
authors.initials: A
authors.lastname: Harman
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Chang
authors.forename: Damian
authors.initials: D
authors.lastname: Dupuy
authors.forename: Peter
authors.initials: P
authors.lastname: Rintels
mesh_terms: D000311:Adrenal Glands / Q000378:metabolism* / Q000473:pathology; D001853:Bone Marrow / Q000378:metabolism* / Q000473:pathology; D005189:False Positive Reactions; D005260:Female; D052203:Ferrosoferric Oxide / Q000493:pharmacokinetics*; D006486:Hemosiderosis / Q000175:diagnosis; D006801:Humans; D007501:Iron / Q000097:blood; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008111:Liver Function Tests; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008875:Middle Aged; D057947:Parenteral Nutrition Solutions / Q000378:metabolism; D013154:Spleen / Q000378:metabolism* / Q000473:pathology
chemical_list: D057947:Parenteral Nutrition Solutions; D007501:Iron; D052203:Ferrosoferric Oxide